Volume | 125,887 |
|
|||||
News | - | ||||||
Day High | 5.12 | Low High |
|||||
Day Low | 4.35 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Synaptogenix Inc | SNPX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.44 | 4.35 | 5.12 | 4.452 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
728 | 125,887 | US$ 4.73 | US$ 594,871 | - | 3.5275 - 47.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
13:33:58 | 34 | US$ 4.92 | USD |
Synaptogenix Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
97.47M | 20.39M | - | 0 | -13.78M | -0.68 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Synaptogenix News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNPX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.43 | 5.12 | 4.34 | 4.53 | 17,401 | 0.5699 | 12.86% |
1 Month | 4.72 | 6.217 | 3.865 | 4.63 | 221,750 | 0.2799 | 5.93% |
3 Months | 5.0825 | 7.2225 | 3.5275 | 5.25 | 555,180 | -0.0826 | -1.63% |
6 Months | 6.50 | 8.775 | 3.5275 | 5.54 | 554,268 | -1.50 | -23.08% |
1 Year | 22.50 | 47.00 | 3.5275 | 11.93 | 660,550 | -17.50 | -77.78% |
3 Years | 187.50 | 362.50 | 3.5275 | 78.86 | 348,821 | -182.50 | -97.33% |
5 Years | 187.50 | 362.50 | 3.5275 | 78.86 | 348,821 | -182.50 | -97.33% |
Synaptogenix Description
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. |